Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes

Journal of Viral Hepatitis

Volumn 12, Issue 4, 2005, Pages 346-356

  Nash, K L ^a   Alexander, G J M ^a   Lever, Andrew M L ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antisense; Hepatitis B; Lentivirus vector; Liver transplant; Ribozyme

Indexed keywords

COMPLEMENTARY RNA; HEPATITIS B VIRUS X PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; RIBONUCLEASE; RIBOZYME; VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; VIRUS INHIBITION;

BASE SEQUENCE; CELL LINE; GENETIC VECTORS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LENTIVIRUS; MOLECULAR SEQUENCE DATA; RNA, ANTISENSE; RNA, CATALYTIC; RNA, MESSENGER; RNA, VIRAL; TRANS-ACTIVATORS;

EID: 21844432688     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00612.x     Document Type: Article

References (43)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455.
2. Zuckerman AJ. More than third of world's population has been infected with hepatitis B virus. Bmj 1999; 318: 1213.
3. Liaw YF, Tai DI, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
4. Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133.
5. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
6. Lau DT, Everhart J, Kleiner DE et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667.
7. Hookoop P, de Man RA, Heitjtink RA et al. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157.
8. Demetris AJ, Todo S, Van Thiel DH et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 1990; 137: 667-676.
9. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of flbrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157.
10. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
11. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-1586.
12. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693.
13. Branch AD. A hitchhiker's guide to antisense and non-antisense biochemical pathways. Hepatology 1996; 24: 1517-1529.
14. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990; 29: 10695-10702.
15. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600.
16. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-591.
17. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
18. Kafri T, Blomer U, Peterson DA et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genetics 1997; 17: 314-317.
19. Ohashi K, Park F, Schwall R et al. Efficient gene transduction to cultured hepatocytes by HIV-1 derived lentiviral vector. Transplant Proc 2002; 34: 1431-1433.
20. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
21. Zufferey R, Nagy D, Mandel RJ et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology 1997; 15: 871-875.
22. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
23. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology 1987; 7: 2745-2752.
24. Nash KL, Lever AML. Green fluorescent protein: green cells don't always indicate gene expression. Gene Therapy 2004; 11: 882-883.
25. Welch PJ, Tritz R, Yei S et al. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4: 736-743.
26. Wu X, Li Y, Crise B et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
27. Zahler MH, Irani A, Malhi H et al. The application of a lentiviral vector for gene transfer in fetal human hepatocytes. J Gene Med 2000; 2: 186-193.
28. Ohashi K, Park F, Kay MA. Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther 2002; 13: 653-663.
29. Tsui LV, Kelly M, Zayek N et al. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002; 20: 53-57.
30. Seppen J, Rijnberg M, Cooreman MP et al. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002; 36: 459-465.
31. Pfeifer A, Kessler T, Yang M et al. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol Ther 2001; 3: 319-322.
32. Tung FYT, Bowen SW. Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci 1998; 3: a11-a15.
33. zu Putlitz J, Wieland S, Blum HE et al. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 1998; 115: 702-713.
34. zu Putlitz J, Yu Q, Burke JM et al. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol 1999; 73: 5381-5387.
35. Kim YK, Junn E, Park I et al. Repression of hepatitis B virus X gene expression by hammerhead ribozymes. Biochem Biophys Res Commun 1999; 257: 759-765.
36. Passman M, Weinberg M, Kew M et al. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun 2000; 268: 728-733.
37. Weinberg M, Passman M, Kew M et al. Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol 2000; 33: 142-151.
38. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA 1991; 88: 6921-6925.
39. Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. Embo J 1994; 13: 2904-2912.
40. Homann M, Rittner K, Sczakiel G. Complementary large loops determine the rate of RNA duplex formation in vitro in the case of an effective antisense RNA directed against the human immunodeficiency virus type 1. J Mol Biol 1993; 233: 7-15.
41. Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res 1995; 23: 4954-4962.
42. Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992; 36: 101-117.
43. Blum HE, Zhang ZS, Galun E et al. Hepatitis B virus X protein is not central to the viral life cycle in vitro. J Virol 1992; 66: 1223-1227.